Aviragen Therapeutics (NASDAQ: AVIR) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $570 thousand.

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.